A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus ...

Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819.

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes ...